1st & Only Oral Steroid-Sparing Therapy Approved for GCA.

GCA patients can rapidly reach remission at 3 months, taper off of steroids in 6 months, and stay in remission out to 1 year. In patients who sustained remission from Week 28–52, remission rates were observed out to 2 years.^1-3

RINVOQ met the primary endpoint of sustained remission* Week 12–52: 46% RINVOQ 15 mg + 26-wk CS taper (n=209) vs 29% placebo + 52-wk CS taper (n=112), P=0.002.³

Explore the Data

*Sustained remission was defined as the absence of GCA signs and symptoms from Week 12 through 52 and adherence to the protocol-defined CS-taper regimen.

CS=corticosteroid; GCA=giant cell arteritis.

INDICATION

RINVOQ is indicated for the treatment of adults with giant cell arteritis (GCA).

Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

Rapid and Substantial
Steroid Reduction^1,3

RINVOQ 15 mg + 26-wk CS taper (n=180) observed a reduction of patients’ median cumulative CS exposure by a substantial numerical difference of 40% relative to those on placebo + 52‍-‍wk CS taper (n=90) (1615 mg vs 2882 mg through Week 52)

Steroid Reduction Data

Durable Remission^2,3

Remission achieved at Week 12 and sustained through 1 year in 46.4% of patients on RINVOQ 15 mg + 26‍-‍wk CS taper, vs 29% on placebo + 52‍-‍wk CS taper (primary endpoint, P=0.002)
In patients who sustained remission from Week 28–52 with RINVOQ, remission rates were observed out to 2 years

Complete Remission Data

Well-Studied
Safety Profile^1,3,4

Safety data with 27 clinical trials across 9 approved indications, including in an older patient population (mean age 71) with GCA

Safety Profile

^†Complete remission was defined as achieving absence of GCA signs and symptoms, adherence to the protocol-defined CS-taper regimen, normalization of ESR (to ≤30 mm/hr), and normalization of hsCRP (to <1 mg/dL).

For GCA, RINVOQ is covered as a FIRST-LINE THERAPY with ~99% PREFERRED combined commercial and Medicare Part D coverage^5†‡

National commercial and Medicare Part D formulary coverage under the pharmacy benefit as of April 2026 in GCA⁵

^†RINVOQ is on a preferred tier or otherwise has preferred status on the plan’s formulary.
^‡Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

See Access Information for Additional Indications

Learn About Patient Support

Please see Important Safety Information, including BOXED WARNING on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, below.

Learn more about these and the full Important Safety Information below

Hear expert insights on RINVOQ and key topics in rheumatology

Tune in as leading rheumatologists discuss clinical data through the lens of real-world experience.

Available On-Demand

Listen on Apple Podcasts

Listen on Spotify

Apple and Apple Podcasts are registered trademarks of Apple Inc.

RINVOQ (upadacitinib) Met Its Primary Endpoint of Sustained Remission from Week 12 through Week 52

Significantly higher rates of sustained remission achieved in patients on RINVOQ 15 mg + 26-wk CS taper vs placebo + 52-wk CS taper^1,3

SUSTAINED REMISSION:

Absence of GCA signs and symptoms from Week 12 through 52 and adherence to the protocol-defined CS-taper regimen.

Prednisone/prednisolone taper schedule from the SELECT-GCA clinical trial

SELECT-GCA CS Taper Schedule for HCPs

For GCA, the recommended dose of RINVOQ is 15 mg once daily in combination with a tapering course of corticosteroids. Download the taper schedule from the SELECT-GCA clinical trial to use as a reference. Patients with GCA who had a disease flare during the trial were provided additional steroids and no longer followed this taper schedule. The starting dose and taper schedule are up to healthcare provider discretion, and this schedule is not intended as direction for healthcare providers.

	Blinded 52-wk CS* Taper (mg)
Baseline	20	30	40	50	60
Week 1	17	25	35	40	50
Week 2	17	20	30	35	40
Week 3	15	17	25	30	35
Week 4	15	17	20	25	30
Week 5	12	15	17	20	25
Week 6	10	15	17	17	20
Week 7	10	12	15	17	17
Week 8	10	10	15	16	17
Week 9	10	10	12	15	15
Week 10	9	10	10	12	15
Week 11	9	10	10	10	12
Week 12	9	9	10	10	10
Week 13	9	9	10	10	10
Week 14	8	9	9	10	10
Week 15+	Taper 1 mg every 4 weeks until 0 mg at Week 46	Taper 1 mg every 4 weeks until 0 mg at Week 48	Taper 1 mg every 4 weeks until 0 mg at Week 50	Taper 1 mg every 4 weeks until 0 mg at Week 51	Taper 1 mg every 4 weeks until 0 mg at Week 52

	Blinded 26-wk CS* Taper (mg)
Baseline	20	30	40	50	60
Week 1	15	25	35	40	50
Week 2	12	20	30	35	40
Week 3	12	15	25	30	35
Week 4	10	12	20	25	30
Week 5	9	12	15	20	25
Week 6	8	10	12	15	20
Week 7	7	9	12	12	15
Week 8	6	8	10	12	12
Week 9	6	7	9	10	12
Week 10	5	6	8	9	10
Week 11	5	6	7	8	9
Week 12	4	5	6	7	8
Week 13	4	5	5	6	7
Week 14	3	4	5	5	6
Week 15+	Taper 1 mg every 2 weeks until 0 mg at Week 20	Taper 1 mg every 2 weeks until 0 mg at Week 22	Taper 1 mg every 2 weeks until 0 mg at Week 24	Taper 1 mg every 2 weeks until 0 mg at Week 25	Taper 1 mg every 2 weeks until 0 mg at Week 26

MEAN (SD) or n (%)	PBO + 52-wk CS Taper (n=112)	RINVOQ 15 mg + 26-wk CS Taper (n=209)	Stopped RINVOQ 15 mg and Switched to PBO^§(n=35)	Continued RINVOQ 15 mg^§(n=68)
	PERIOD 1 (WEEK 0–52)		PERIOD 2 (WEEK 52–104)^‡
Female, n (%)	77 (68.8)	156 (74.6)	27 (77.1)	51 (75.0)
Age (years), mean (SD)	71.6 (7.3)	70.8 (7.3)	69.9 (6.7)	71.3 (8.2)
Age group (years), n (%)
<65	17 (15.2)	42 (20.1)	9 (25.7)	12 (17.6)
≥65 to <75	59 (52.7)	102 (48.8)	16 (45.7)	34 (50)
≥75	36 (32.1)	65 (31.1)	10 (28.6)	22 (32.4)
BMI (kg/m²), mean (SD)	25.8 (4.3)	25.3 (4.6)	24 (3.7)	25 (4.2)
Prior use of IL-6 inhibitor, n (%)	7 (6.2)	9 (4.3)	4 (11.4)	2 (2.9)
Baseline CS dose (mg), mean (SD)	34.6 (11.9)	34.6 (12.7)	32.3 (12.4)	33.1 (12.4)
New onset of GCA, n (%)	76 (67.9)	148 (70.8)	26 (74.3)	49 (72.1)
Relapsing GCA, n (%)	36 (32.1)	61 (29.2)	9 (25.7)	19 (27.9)
Disease duration since diagnosis (days), mean (SD)
New-onset disease	38.2 (14.8)	39.5 (28.1)	39.9 (13.7)	46.0 (45.5)
Relapsing disease	665.7 (816.3)	664.9 (687.5)	931.6 (769.7)	757.4 (770.6)
ESR (mm/hr), mean (SD)	21.7 (25.5)	19.5 (17.5)	15.9 (12.8)	20.9 (17.9)
hsCRP (mg/dL), median (min, max)	0.23 (0.02, 5.83)	0.24 (0.02, 10.10)	0.27 (0.02, 10.0)	0.24 (0.02, 3.5)
History of PMR, n (%)	69 (61.6)	109 (52.2)	19 (54.3)	35 (51.5)
History of TAB, n (%)	44 (39.3)	86 (41.1)	17 (48.6)	27 (39.7)
Evidence of LVV, n (%)	81 (73.0)	159 (76.1)	26 (74.3)	52 (76.5)
Ischemia-related vision loss, n (%)	22 (19.6)	20 (9.6)	5 (14.3)	2 (2.9)

GCA patients can rapidly reach remission at 3 months, taper off of steroids in 6 months, and stay in remission out to 1 year. In patients who sustained remission from Week 28–52, remission rates were observed out to 2 years.1-3

RINVOQ met the primary endpoint of sustained remission* Week 12–52: 46% RINVOQ 15 mg + 26-wk CS taper (n=209) vs 29% placebo + 52-wk CS taper (n=112), P=0.002.3

RINVOQ met the primary endpoint of sustained remission* Week 12–52: 46% RINVOQ 15 mg + 26-wk CS taper (n=209) vs 29% placebo + 52-wk CS taper (n=112), P=0.002.3

Rapid and Substantial Steroid Reduction1,3

Durable Remission2,3

Well-Studied Safety Profile1,3,4

For GCA, RINVOQ is covered as a FIRST-LINE THERAPY with ~99% PREFERRED combined commercial and Medicare Part D coverage5†‡

Hear expert insights on RINVOQ and key topics in rheumatology

RINVOQ (upadacitinib) Met Its Primary Endpoint of Sustained Remission from Week 12 through Week 52

Significantly higher rates of sustained remission achieved in patients on RINVOQ 15 mg + 26-wk CS taper vs placebo + 52-wk CS taper1,3

Prednisone/prednisolone taper schedule from the SELECT-GCA clinical trial

INDICATIONS & IMPORTANT SAFETY INFORMATION1

INDICATION1

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)

SERIOUS INFECTIONS

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

HYPOGLYCEMIA IN PATIENTS WITH DIABETES

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

MEDICATION RESIDUE IN STOOL

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS

INDICATIONS & IMPORTANT SAFETY INFORMATION1

INDICATIONS1

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)

SERIOUS INFECTIONS

MORTALITY

MALIGNANCIES

MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)

THROMBOSIS

HYPERSENSITIVITY

GASTROINTESTINAL PERFORATIONS

HYPOGLYCEMIA IN PATIENTS WITH DIABETES

LABORATORY ABNORMALITIES

EMBRYO-FETAL TOXICITY

VACCINATION

MEDICATION RESIDUE IN STOOL

LACTATION

HEPATIC IMPAIRMENT

ADVERSE REACTIONS

GCA patients can rapidly reach remission at 3 months, taper off of steroids in 6 months, and stay in remission out to 1 year. In patients who sustained remission from Week 28–52, remission rates were observed out to 2 years.^1-3

RINVOQ met the primary endpoint of sustained remission* Week 12–52: 46% RINVOQ 15 mg + 26-wk CS taper (n=209) vs 29% placebo + 52-wk CS taper (n=112), P=0.002.³

RINVOQ met the primary endpoint of sustained remission* Week 12–52: 46% RINVOQ 15 mg + 26-wk CS taper (n=209) vs 29% placebo + 52-wk CS taper (n=112), P=0.002.³

Rapid and Substantial
Steroid Reduction^1,3

Durable Remission^2,3

Well-Studied
Safety Profile^1,3,4

For GCA, RINVOQ is covered as a FIRST-LINE THERAPY with ~99% PREFERRED combined commercial and Medicare Part D coverage^5†‡

Significantly higher rates of sustained remission achieved in patients on RINVOQ 15 mg + 26-wk CS taper vs placebo + 52-wk CS taper^1,3

INDICATIONS & IMPORTANT SAFETY INFORMATION¹

INDICATION¹

INDICATIONS & IMPORTANT SAFETY INFORMATION¹

INDICATIONS¹